Skip to content

HYDrochlorothiazidE compared to valsartan to treat arterial hypertension in patients with Hypertrophic obstructive CardioMyopathy – the multicenter, randomized, double-blind, controlled, crossover HYDE-HCM Trial

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-520086-31-00
Acronym
NV-2025-01
Enrollment
40
Registered
2025-12-29
Start date
2026-01-07
Completion date
Unknown
Last updated
2025-12-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertrophic cardiomyopathy

Brief summary

Difference in absolute change of peak LVOT gradient at rest from before to after the treatment period between the two interventions

Detailed description

Difference of absolute changes between the two intervention groups of Peak LVOT gradient after Valsalva-Maneuver, Difference of absolute changes between the two intervention groups of left ventricular systolic pressure calculated from brachial blood pressure and LVOT gradient, Difference of absolute changes between the two intervention groups of Kansas City Cardiomyopathy Questionnaire (KCCQ-23 Score), Difference of absolute changes between the two intervention groups of EQ5D5L score, Difference of absolute changes between the two intervention groups of NT-proBNP, Difference of absolute changes between the two intervention groups of High-sensitive Troponin T/I, Difference of absolute changes between the two intervention groups of Interleukin-6, Difference of absolute changes between the two intervention groups of pVO2 during CPET (CPET sub-study), Difference of absolute changes between the two intervention groups of mean systolic postprandial office blood pressure, Difference of absolute changes between the two intervention groups of mean diastolic postprandial office blood pressure, Number of serious adverse events (SAEs), Difference of absolute changes between the two intervention groups of NYHA class

Interventions

DRUGHCT G.L. 50 mg-Tabletten
DRUGValsartan Sandoz 160 mg - Filmtabletten

Sponsors

Medical University Of Graz
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Difference in absolute change of peak LVOT gradient at rest from before to after the treatment period between the two interventions

Secondary

MeasureTime frame
Difference of absolute changes between the two intervention groups of Peak LVOT gradient after Valsalva-Maneuver, Difference of absolute changes between the two intervention groups of left ventricular systolic pressure calculated from brachial blood pressure and LVOT gradient, Difference of absolute changes between the two intervention groups of Kansas City Cardiomyopathy Questionnaire (KCCQ-23 Score), Difference of absolute changes between the two intervention groups of EQ5D5L score, Difference of absolute changes between the two intervention groups of NT-proBNP, Difference of absolute changes between the two intervention groups of High-sensitive Troponin T/I, Difference of absolute changes between the two intervention groups of Interleukin-6, Difference of absolute changes between the two intervention groups of pVO2 during CPET (CPET sub-study), Difference of absolute changes between the two intervention groups of mean systolic postprandial office blood pressure, Difference of absolu

Countries

Austria

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026